MetLife 10-Q: Q3 Net Income $2.4B, Adjusted EPS $2.85, $86M Assumption-Review Hit
MET sits 49% above its 52-week low of $67.33.
Summary
MetLife's Q3 10-Q confirms the already-reported $2.4 billion quarterly net income and $2.85 adjusted EPS, while disclosing an $86 million after-tax actuarial assumption-review loss and a $7.2 billion year-to-date drop in accumulated other comprehensive income to $(25.3) billion.
Key Events · Earnings and Guidance · MET
-
Q3 Earnings Confirmed in Full 10-Q
Net income available to common shareholders was $2,351 million for Q3 2026 versus $818 million a year earlier; nine-month net income was $4,196 million versus $2,395 million.
-
Assumption Review Swings to a Loss
The actuarial assumption review produced an $86 million after-tax loss versus a $102 million gain in Q3 2025, a $188 million swing, driven by long-term care lapse and premium-rate assumption updates and less favorable mortality in pension risk transfer.
-
Book Value Hit by Bond Marks
Accumulated other comprehensive income fell to $(25,304) million from $(18,084) million at December 31, 2025, as gross unrealized losses on available-for-sale securities rose $15.8 billion to $43.9 billion on higher interest rates.
-
Buyback and Debt Actions
MetLife repurchased 25,627,945 shares for $2.1 billion in the first nine months, leaving $2,972 million on the August 5, 2026 $3.0 billion authorization; it also issued $1.0 billion of 5.850% subordinated debentures due 2056 in February 2026.
Analysis · MET · Finance
The headline numbers were already out on November 4, but the full 10-Q is where the balance-sheet story lives. Book value took a hit: accumulated other comprehensive income fell to $(25.3) billion from $(18.1) billion at year-end as gross unrealized losses on the bond portfolio widened by $15.8 billion to $43.9 billion on higher rates. That is an accounting mark, not a credit event — the company says it does not intend to sell and expects to recover amortized cost — but it does erode reported equity and the capital cushion regulators and rating agencies watch. Against that, the actuarial assumption review swung to an $86 million after-tax loss from a $102 million gain a year ago, mostly long-term care lapse and premium-rate assumptions plus weaker mortality in pension risk transfer. Capital return continues: 25.6 million shares repurchased for $2.1 billion in the first nine months, with $2.97 billion left on the August authorization.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MET was trading at $100.00 on NYSE in the Finance sector, with a market capitalization of approximately $63.4B. The 52-week trading range was $67.33 to $106.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.